Oric Pharmaceuticals

Biotechnology
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

$972.9M

Market Cap • 2/13/2026

2014

(12 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country